Molecules to Markets

We introduce a ‘road map’ to put into context the many functional activities that work in parallel, as well as key decision points.

Product profile
How we develop a vision of a new product and then identify what needs to be done to make it happen.
Research / Discovery – how leads are identified—from computer design or the screening of millions of molecules.

Intellectual property – how we obtain commercial protection for molecules and techniques.

From idea to candidate—a summary of how we decide which compounds are selected for intensive testing—to see if they will be valuable drugs.

Chem/Pharm Dev – how molecules become usable medicines; how lab scale compounds can transfer to industrial scale processes .

From bench to factory - how we assess ‘developability’ - can we meet and produce new medicines to quality and cost—will we make a profit?!
Day 2 09:00—17:00

Safety assessment – how we develop confidence to test drugs in humans—from the ‘first time in man’ decision toward longer and longer studies.

Clinical study – how safety and efficacy are determined—from early volunteer studies through to trials in hundreds of patients

From new drug to POC—how we assess ‘Proof of Concept’ - and decide which drugs qualify for the huge investment of major clinical trials.

Health outcomes – how our major clinical trials generate evidence that new drugs genuinely improve experience of diseases and are real value for money.

From Phase 3 to Market—do we have the confidence to make the biggest investment of all—the decision to launch a product worldwide?
Day 2 09:00—17:00

Safety assessment – how we develop confidence to test drugs in humans—from the ‘first time in man’ decision toward longer and longer studies.

Clinical study – how safety and efficacy are determined—from early volunteer studies through to trials in hundreds of patients

From new drug to POC—how we assess ‘Proof of Concept’ - and decide which drugs qualify for the huge investment of major clinical trials.

Health outcomes – how our major clinical trials generate evidence that new drugs genuinely improve experience of diseases and are real value for money.

From Phase 3 to Market—do we have the confidence to make the biggest investment of all—the decision to launch a product worldwide?
Day 3 09:00—12:30

Regulatory – how we convince government bodies worldwide that our new drugs are effective, safe and are valuable additions to healthcare systems.

Sales and Brand development – how demand is created with customers and how a new product builds a reputation with expert medics and patients.

From launch to peak sales—how can we continuously develop both the product and market perceptions so that sales continue to rise?